TWO STUDIES DEMONSTRATE SIGNIFICANT BENEFIT OF ELOXATIN– BASED CHEMOTHERAPY COMBINED WITH BEVACIZUMAB IN ADVANCED COLORECTAL CANCER
TWO STUDIES DEMONSTRATE SIGNIFICANT BENEFIT OF ELOXATIN– BASED CHEMOTHERAPY COMBINED WITH BEVACIZUMAB IN ADVANCED COLORECTAL CANCER Positive Results of TREE-2 and ECOG 3200 Trials Presented at the 2005 Gastrointestinal Cancers Symposium in Hollywood, Florida PARIS, France, January 31, 2005 – Sanofi-aventis (NYSE: SNY) announced today preliminary results of two large prospective trials evaluating the safety and efficacy of Eloxatin® (oxaliplatin for injection) -based regimens in the treatment of metastatic colorectal cancer. These data were presented at the Gastrointestinal Cancers Symposium,